Astel­las, Seagen pave the way for Pad­cev's glob­al roll­out with full con­fir­ma­to­ry da­ta for urothe­lial can­cer in hand

Astel­las and Seagen made a big splash with their Nectin-4 tar­get­ing ther­a­py Pad­cev in late 2019, scor­ing a con­di­tion­al FDA ap­proval to tar­get urothe­lial can­cer. Now, the re­sults are in for the con­fir­ma­to­ry study for that in­di­ca­tion, and it looks like a re­sound­ing win for Pad­cev.

Astel­las and Seagen’s Pad­cev ex­tend­ed pa­tients’ lives to an av­er­age 12.9 months com­pared with nine months for a chemo con­trol, ac­cord­ing to full da­ta from the Phase III EV-301 study pre­sent­ed Fri­day at the vir­tu­al AS­CO GU meet­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER